Most protocols run 6-12 weeks to address acute healing needs
Costes S, Langen R, Gurlo T, Matveyenko AV, Butler PC
In the private insurance market, 57.4 million adults under 65 could be potentially eligible for GLP-1 drugs Over 2 in 5 (42%) adults under 65 with private insurance could be eligible for GLP-1 drugs, based on current Food and Drug Administration (FDA) indications
GLP-1 medications may not be appropriate for all patients and can cause serious side effects
The relevant HRs and their 95% confidence intervals (95% CIs) were extracted from these studies
How It Works Compounded Tirzepatide (GLP-1/GIP) is a once-weekly injectable therapy that mimics dual incretin hormones, potentially offering stronger support for appetite regulation and metabolic balance than GLP-1 alone